CVRX vs. ARAY, OBIO, QIPT, DRTS, PROF, CLPT, DCTH, TELA, RCEL, and ANGO
Should you be buying CVRx stock or one of its competitors? The main competitors of CVRx include Accuray (ARAY), Orchestra BioMed (OBIO), Quipt Home Medical (QIPT), Alpha Tau Medical (DRTS), Profound Medical (PROF), ClearPoint Neuro (CLPT), Delcath Systems (DCTH), TELA Bio (TELA), AVITA Medical (RCEL), and AngioDynamics (ANGO). These companies are all part of the "surgical & medical instruments" industry.
CVRx (NASDAQ:CVRX) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends, community ranking and profitability.
CVRx has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Accuray has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
Accuray received 315 more outperform votes than CVRx when rated by MarketBeat users. Likewise, 65.67% of users gave Accuray an outperform vote while only 57.14% of users gave CVRx an outperform vote.
75.3% of CVRx shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 18.9% of CVRx shares are held by company insiders. Comparatively, 3.8% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Accuray has a net margin of -4.99% compared to CVRx's net margin of -123.58%. Accuray's return on equity of -42.34% beat CVRx's return on equity.
Accuray has higher revenue and earnings than CVRx. Accuray is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.
CVRx presently has a consensus target price of $16.60, suggesting a potential upside of 104.94%. Accuray has a consensus target price of $8.25, suggesting a potential upside of 371.43%. Given Accuray's stronger consensus rating and higher possible upside, analysts clearly believe Accuray is more favorable than CVRx.
In the previous week, CVRx had 14 more articles in the media than Accuray. MarketBeat recorded 36 mentions for CVRx and 22 mentions for Accuray. CVRx's average media sentiment score of -0.10 beat Accuray's score of -0.27 indicating that CVRx is being referred to more favorably in the media.
Summary
Accuray beats CVRx on 11 of the 18 factors compared between the two stocks.
Get CVRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
